
Please try another search
By Sam Boughedda
Oppenheimer analysts said in a note Friday that Sarepta Therapeutics Sarepta Therapeutics Inc (NASDAQ:SRPT) is "ripe" for a takeover.
The analysts, who have an Outperform rating and a $150 price target on the stock, explained that while the M&A Buy thesis for Sarepta has been explained well, they believe the timing might be "more ripe currently."
Sarepta Therapeutics shares are down 0.4% at the time of writing. However, they have climbed 27% so far in 2022.
Oppenheimer upgraded Sarepta in December last year, stating it had a "best-in-class rh74 AAV capsid."
In today's note, the analysts wrote: "The best-in-class safety profile for SRPT's rh74 AAV vector is bolstered by the company's leading manufacturing expertise in this area; possibly creating a significant moat around the muscular dystrophy programs. The LGMD programs and the RNA-based PPMO programs are underappreciated. We stay bullish."
"The optics for a SRPT takeout are easy, in our view: (1) a leader in gene therapy, (2) a leader in muscular dystrophies (DMD, LGMDs), (3) a fairly diverse pipeline with RNA-targeted therapies and gene editing approaches also, and (4) a strong financial backdrop to achieve its objective to be a leader in genetic medicines in rare diseases. We add some nuance to these views," they added.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.